Improving patient access to Comprehensive Genomic Profiling for patients in Malaysia
Selangor, November 8, 2023 – Roche (Malaysia) Sdn Bhd, the pharmaceutical division and Roche Diagnostics (M) Sdn Bhd, the diagnostics division, recently signed a Memorandum of Understanding (MoU) with Premier Integrated Labs (PILs) in its bid to increase awareness and understanding of Comprehensive Genomic Profiling (CGP) and improve patient access to CGP for patients in Malaysia.
Comprehensive Genomic Profiling (CGP) tailors personalised cancer treatment for the patients. With a single test, CGP can analyse a broad panel of genes that is known to drive cancer growth. This type of testing produces comprehensive patient reports with broad and deep assessments of the possible underlying cancer drivers.1,2
Heng Chai Yin, General Manager of Roche Diagnostics (M) Sdn. Bhd. shared, “At Roche, we have a passion for innovation and we strive to improve patient access in Malaysia as healthcare that is built on people’s needs, strong data and clinical insights is healthcare that saves lives.” She added that Roche understands the importance the role cancer genomics can play and is actively working towards increasing the awareness and understanding of CGP, staying true to Roche’s vision of continuously innovating diagnostics, shaping healthcare and changing lives.
She further added, “Our partnership with Premier Integrated Labs is a testament to the power of collaboration and a testament to our shared values, aspirations, and the belief that together, we can shape a brighter future for a better Malaysia.”
Mr. Hareeff Muhammed, Chief Executive Officer of Premier Integrated Labs expressed his enthusiasm stating, “We are thrilled to formalise our partnership with Roche, marking a landmark moment that holds the potential to reshape healthcare in Malaysia. Our commitment to raising awareness about CGP and ensuring broader access to this innovative medical advancement reinforces our dedication to personalised medicine, unlocking the power of genetics for more precise, tailored treatments.”
He further emphasised, “Together with Roche, we aspire to make CGP accessible to all patients, transcending socio-economic boundaries and geographic constraints. This partnership signifies our shared vision for a healthier and brighter future in Malaysia healthcare.”
“We are committed to evolving the standards of care in cancer and helping patients live longer, better lives. We also want to deliver the best care for each person by shifting away from a one-size-fits all approach to personalising treatment for each cancer patient,” said Deepti Saraf, General Manager of Roche (Malaysia) Sdn. Bhd. She also added that the signing of this MoU represents a significant milestone in Roche’s commitment to advancing healthcare in Malaysia and beyond. “We look forward to partnerships similar to this in the future, as we are committed to ensuring that patient and population health can be leapfrogged to personalised care,” Deepti added.
